Several clinical scoring systems have been developed for the differential diagnosis of thrombotic microangiopathies (TMAs), all to predict and identify patients with ADAMTS13 deficiency and to start treatment as soon as possible. This evidence concerns the gene ADAMTS13 and Genetic thrombotic microangiopathy.